INT242944

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 3.18
Pain Relevance 0.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PDE5A) signal transduction (PDE5A) cellular_component (PDE5A)
Anatomy Link Frequency
nervous system 2
PDE5A (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 8 94.24 High High
Multiple sclerosis 14 93.96 High High
Angina 8 75.48 Quite High
Neuropathic pain 2 71.04 Quite High
Inflammation 8 63.32 Quite High
Opioid 2 60.32 Quite High
antagonist 8 58.72 Quite High
ketamine 2 54.40 Quite High
Central nervous system 30 53.28 Quite High
headache 6 44.44 Quite Low
Disease Link Frequency Relevance Heat
Neurological Disease 8 99.60 Very High Very High Very High
Amnesia 6 94.92 High High
Pain 6 94.24 High High
Demyelinating Disease 14 93.96 High High
Reprotox - General 2 74 92.68 High High
Disease 62 91.72 High High
Pressure And Volume Under Development 16 87.00 High High
Increased Venous Pressure Under Development 10 84.88 Quite High
Cv Unclassified Under Development 10 84.20 Quite High
Benign Prostatic Hypertrophy 224 78.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Use of PDE5 inhibitors in other nervous system diseases
Negative_regulation (inhibitors) of Localization (Use) of PDE5 in nervous system associated with neurological disease
1) Confidence 0.35 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518390 Disease Relevance 0.91 Pain Relevance 0.33
Reported PDE5 inhibitors can be divided into the following classes: 1) cGMP-based, represented by sildenafil (Viagra) and vardenafil (Levitra) (Pfizer, Bayer, Sheering-Plough), 2) ?
Negative_regulation (inhibitors) of Localization (Reported) of PDE5
2) Confidence 0.35 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518390 Disease Relevance 0.98 Pain Relevance 0.26
Current US labeling for sildenafil, tadalafil, and vardenafil states that these phosphodiesterase type 5 inhibitors should be started at the lowest recommended dose for patients stabilized on ?
Negative_regulation (labeling) of Localization (started) of phosphodiesterase type 5
3) Confidence 0.03 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682383 Disease Relevance 0.65 Pain Relevance 0
Current US labeling for sildenafil, tadalafil, and vardenafil states that these phosphodiesterase type 5 inhibitors should be started at the lowest recommended dose for patients stabilized on ?
Negative_regulation (inhibitors) of Localization (started) of phosphodiesterase type 5
4) Confidence 0.03 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682383 Disease Relevance 0.64 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox